Journal of Bacteriology · 2019 · 38 citations · 35 references
Life SciencesBiochemistryPharmacologyDrug DiscoveryEnzymologyLipid BiochemistryAntibacterial PharmacologyAntibiotic ResistanceEnzyme InhibitionHelicobacter Pylori Eradication TherapyLipid MetabolismDruggable Target DiscoveryGastric EnzymesGastric ResistanceHelicobacter Pylori EradicationHelicobacter Pylori InfectionHelicobacter Pylori PathogenesisMolecular Drug Resistance
The increasing prevalence of multidrug-resistant Helicobacter pylori strains has created an urgent need for alternative therapeutic regimens that complement the current antibiotic treatment strategies for H. pylori eradication; however, this is greatly hampered due to a lack of “druggable” targets. Although the CFAs are present in H. pylori cytoplasmic membranes at high levels, their physiological role has not been established. In this report, deletion of the CFA synthase CfaS was shown to attenuate acid and drug resistance, immune escape, and gastric colonization of H. pylori . These findings were validated by inhibition of the CfaS activity with the tool compound dioctylamine. These studies identify this enzyme as an attractive target for further drug discovery efforts against H. pylori .
35
The complete genome sequence of the gastric pathogen Helicobacter pylori
Jean-F. Tomb, Owen White, Anthony R. Kerlavage et al. · Nature · 1997 · 3.6K citations · Full text
Management of <i>Helicobacter pylori</i> infection—the Maastricht V/Florence Consensus Report
Peter Malfertheiner, Françis Mégraud, Colm O’Morain et al. · Gut · 2016 · 2.9K citations · Full text